Russia trials first mRNA melanoma vaccine in groundbreaking cancer therapy

Russia trials first mRNA melanoma vaccine in groundbreaking cancer therapy

Vials of vaccine next to a box of color samples on a blue surface, with text visible on the vials and a scale beside them.

Russia trials first mRNA melanoma vaccine in groundbreaking cancer therapy

Russia has begun treating its first patient with an experimental mRNA vaccine for skin melanoma. The vaccine, called Neonka-Vac, was approved for use in November 2025 and marks a new approach in personalised cancer therapy. A 60-year-old man from the Kursk region became the first to receive the treatment in early April 2026. The patient, who had few remaining treatment options, started the course in April and is due for around ten more doses. His next injection is scheduled for early May, between the public holidays, at a regional oncology clinic in Kursk. Doctors are closely monitoring his progress under supervised care.

Neonka-Vac was developed through a collaboration between the Gamaleya National Research Center, the Blokhin National Medical Research Center of Oncology, and the A.F. Tsyb Medical Radiological Research Center. Unlike traditional treatments, this vaccine is custom-built using the molecular and genetic details of the patient’s tumour. Early blood tests have shown minor but positive changes in the man’s immune response. While the results remain preliminary, they offer the first signs of progress since the treatment began.

The patient’s ongoing treatment will continue over the coming months. If successful, Neonka-Vac could open new possibilities for targeted melanoma therapy in Russia. For now, medical teams are focusing on his response to the next scheduled doses in May.

Neueste Nachrichten